BCM
PTCT icon

Bayesian Capital Management’s PTC Therapeutics PTCT Stock Holding History

Bayesian Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,700
Closed -$399K – 1025
2022
Q1 		$399K Buy
+10,700
New +$412K 0.06% 445
2018
Q2 		– Sell
-13,054
Closed -$353K – 691
2018
Q1 		$353K Buy
+13,054
New +$331K 0.09% 358

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Bayesian Capital Management's PTCT Position: Q2 2022 in Review

Bayesian Capital Management sold out of PTC Therapeutics (PTCT) in Q2 2022, closing a stake of 10,700 shares — an estimated $399K sold.

Bayesian Capital Management first reported a position in PTCT in Q1 2018 and held it in 2 quarters. The position peaked at $399K in Q1 2022. 180 funds tracked by Wall St. Rank hold PTCT as of Q2 2022.

  • Bayesian Capital Management reported no remaining PTC Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Bayesian Capital Management sold 10,700 PTC Therapeutics shares in Q2 2022, an estimated $399K.
  • Bayesian Capital Management first reported a position in PTC Therapeutics in Q1 2018 and held it in 2 quarters.
  • Bayesian Capital Management's PTC Therapeutics position peaked at $399K in Q1 2022.
  • 180 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2022.

Based on Bayesian Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.